Evidence map›Paper›PMID 39652530›Full record

ArticlePloS one2024

Comparison between DSQIID total / sub-item scores and plasma p-tau elevation in adults with Down's syndrome.

Makiko Shinomoto, Chisen Takeuchi, Harutsugu Tatebe, Fukiko Kitani-Morii, Takuma Ohmichi, Yuzo Fujino, Kanako Menjo, Naoto Terada, Miho Osako, Yoko Mochizuki and 4 more

Abstract readComparative Study
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Makiko ShinomotoDepartment of Neurology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Chisen TakeuchiDepartment of Neurology, Tokyo Metropolitan Kita Medical and Rehabilitation Center for the Disabled, Tokyo, Japan.
Harutsugu TatebeDepartment of Functional Brain Imaging, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.
Fukiko Kitani-MoriiDepartment of Neurology, Kyoto Prefectural University of Medicine, Kyoto, Japan.ORCID 0000-0002-7959-4758
Takuma OhmichiDepartment of Neurology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Yuzo FujinoDepartment of Neurology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Kanako MenjoDepartment of Neurology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Naoto TeradaHananoki Medical Welfare Center, Kyoto, Japan.
Miho OsakoDepartment of Neurology, Tokyo Metropolitan Kita Medical and Rehabilitation Center for the Disabled, Tokyo, Japan.ORCID 0000-0002-5088-2879
Yoko MochizukiDepartment of Neurology, Tokyo Metropolitan Kita Medical and Rehabilitation Center for the Disabled, Tokyo, Japan.
Satoshi TeramukaiDepartment of Biostatistics, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Takahiko TokudaDepartment of Genetic Medicine, Jikei University, Tokyo, Japan.
Toshiki MizunoDepartment of Neurology, Kyoto Prefectural University of Medicine, Kyoto, Japan.ORCID 0000-0002-7907-8243
Takashi KasaiDepartment of Neurology, Kyoto Prefectural University of Medicine, Kyoto, Japan.ORCID 0000-0002-6424-0738

Funding

Wellcome Trust FC001002
6 · The paper itself

Abstract

The Dementia Screening Questionnaire for Individuals with Intellectual Disabilities (DSQIID) is an appropriate screening tool for detecting dementia in Down's syndrome patients. However, whether this questionnaire reflects the neuropsychiatric signs of biomarker-confirmed Alzheimer's disease in DS (DS-AD) remains unknown. To address this issue, we compared the plasma phosphorylated tau (P181tau: p-tau) level of a representative AD biomarker with the total score and each sub-score of the DSQIID. The DSQIID was completed by 43 of the 56 individuals enrolled in the study. The DSQIID total scores tended to be positively associated with age, and some sub-scores increased in an age-dependent manner. DSQIID total scores and some sub-scores were also positively correlated with plasma p-tau levels, while all significant correlations disappeared after adjusting for age. Moreover, one sub-score appeared to have a significant negative correlation with plasma p-tau levels after adjusting for age. The DSQIID likely reflects age-associated behavioral changes in patients with DS. Meanwhile, their scores did not correlate with plasma p-tau after adjusting for age, suggesting that there might be room for improvement in the DSQIID for detecting DS-AD.

Indexed as

BiomarkersDown Syndrometau ProteinsAdultAgedAlzheimer DiseaseFemaleHumansIntellectual DisabilityMaleMiddle AgedPhosphorylationSurveys and QuestionnairesYoung AdultBiomarkerstau Proteins

Identifiers

PMID39652530
PMCPMC11627409

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.